Fig. 3.
Percentage of a Th1, b Th2, c Th17 and d Treg cells at baseline, during and after therapy. Lenalidomide was administered on weeks 1–16 and alemtuzumab weeks 5–16. * p < 0.05, ** p < 0.01, *** p < 0.001
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.